FDA Orange Book · active-ingredient family
Triptorelin pamoate
Triptorelin pamoate is approved in 4 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:TRIPTODUR KIT · NDA 208956
4
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · for suspension, extended release, injectable
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| TRIPTODUR KITRLD | AZURITY | NDA 208956 | — | Jun 29, 2017 | |
| TRELSTARRLD | VERITY | NDA 022437 | — | Mar 10, 2010 | |
| TRELSTARRLD | VERITY | NDA 021288 | — | Jun 29, 2001 | |
| TRELSTARRLD | VERITY | NDA 020715 | — | Jun 15, 2000 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10166181 | Jun 30, 2029 | in 3 yr 1 mo | Product |
Triptorelin pamoate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
